• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Kahn Swick & Foti

Kahn Swick & Foti represents investors in securities fraud class actions, as well as shareholders and consumers harmed by corporate wrongdoing.

  • About Us
    • About Our Firm
    • Institutional Investor Services
    • KSF in the Community
    • Careers at KSF
    • Contact Us
  • Attorneys
  • Practice Areas
    • Securities Class Action Litigation
    • Corporate Governance And Derivative Litigation
    • Consumer Protection Litigation
    • Shareholder Mergers and Acquisitions Class Action Litigation
    • Antitrust Litigation
  • Current Cases
  • KSF News
  • Client Login
  • Asset Recovery Services
  • Contact KSF

Plaintiffs Win Class Certification in Chicago Bridge & Iron Securities Litigation

Home»News»Plaintiffs Win Class Certification in Chicago Bridge & Iron Securities Litigation

On March 23, 2020, the Honorable Lorna G. Schofield certified a class of shareholders of Chicago Bridge & Iron Company N.V. (“CB&I”) in a lawsuit arising from Defendants’ alleged material misrepresentations and omissions regarding the performance of, and accounting relating to, CB&I’s nuclear business. The case is In re Chicago Bridge & Iron Company N.V. Securities Litigation, No. 1:17-cv-1580, pending in the United States District Court for the Southern District of New York.  Judge Schofield appointed KSF as Class Counsel and certified a Class of investors that includes purchasers of common stock of Chicago Bridge & Iron Company N.V. on the NYSE during a Class Period from October 30, 2013, through June 23, 2015, excluding Defendants and their affiliates.

Filed Under: News

Previous Post: « KSF Appointed Co-Lead Counsel in Cleco Litigation
Next Post: KSF Appointed Co-Lead Counsel in Qudian Inc. Securities Litigation »

Primary Sidebar

Current Cases

Cabot Oil & Gas Corporation (NYSE: COG)

Amyris, Inc. (NasdaqGS: AMRS)

Obalon Therapeutics, Inc. (NasdaqGS: OBLN)

Coherent, Inc. (NasdaqGS: COHR)

Penumbra, Inc. (NYSE: PEN)

Anchiano Therapeutics Ltd. (NasdaqGS: ANCN)

see more»
 

Join Our Mailing List

To receive news of interest to shareholders and consumers and learn about potential new cases, you may join our mailing list by entering your email below.

Terms and Conditions | Privacy Notice

© 2006-2021 Copyright. All rights reserved Kahn Swick & Foti LLC · New Orleans · New York — Kahn Swick & Foti LLP · San Francisco

We recently updated our Privacy Policy. We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.OkPrivacy policy